PSMα3N22Y shows decreased activation of FPR1. by Gordon Y. C. Cheung (337723)

Renin–angiotensin–aldosterone system inhibition with losartan significantly inhibited transforming growth factor-β1/Smads pathway and decreased Snail expression in vitro. by Chiao-Yin Sun (174213)

“…<p>A: ELISA analysis showed that losartan (1, 10, and 100 uM) significantly decreased the transforming growth factor-β1 concentration in the culture medium of PKSV cells treated with indoxyl sulfate (IS) (50 mg/L) and <i>p</i>-cresol sulfate (PCS) (50 mg/L). …”

The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

“…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”

Dose response of airways to Methacholine shows a decreased contractility in <i>GSTCD</i>^-/- mouse lungs following LPS treatment. by Bo Liu (127343)

Changes in the melting points of each formulation of 0.1% FLU ophthalmic suspensions. by Tokio Obata (10783047)

Required soil organic carbon content and maximum strain energy density as a function of normalized water content for clay contents of 16% and 50%. by Siul Ruiz (757454)

Dynamics of CHT internalization are altered by acute insulin treatment. by Katherine J. Fishwick (768451)

FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD₅₀ = 8.4 μM, p ≤ 0.05). …”

Deletion of <i>bipA</i> in pathogenic <i>S</i>. Typhimurium strains resulted in reduced invasion into HCT116 cells. by Eunsil Choi (8271039)

Color data collection points on the body of ornamental shrimp. by Wei-Wei Hou (3405947)

MTT assay shows that the cells exposed to periostin siRNA showed a significant decrease in IC50 among the DDP, EPI, and DTX compared with the control siRNA group (control group) (<i>P</i><0.01). by Dongyang Xu (303547)

“…<p>MTT assay shows that the cells exposed to periostin siRNA showed a significant decrease in IC50 among the DDP, EPI, and DTX compared with the control siRNA group (control group) (<i>P</i><0.01).…”

Fitting curve of rock E₅₀. by Junxia Zhou (14381598)

A37 increases the M1 protein stability and viral pathogenicity of H5N6 virus. by Chenxi Wang (284364)

Decreased expression of 14-3-3 θ, β, γ, and Chk1 protects against Vpr- and HIV-1 (-)-induced cell cycle arrest by Diane L Bolton (92098)

<i>Bbs1</i>^{<i>M390R/M390R</i>} mice have decreased hippocampal proliferation. by Thomas K. Pak (10686881)

“…At P30, mice were started on BrdU injections (2x50mg/kg) for five days. At P44, mice were taken down. …”

Control group common bigram words (Top 50) before and after pandemic. by Yuxuan Cai (19226202)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Proliferative potential decreases and <i>p16</i> transcripts increase in the presence of PGE₂ and iso-PGE₂. by Jennifer P. Chou (576226)

A Functional 12T-Insertion Polymorphism in the <i>ATP1A1</i> Promoter Confers Decreased Susceptibility to Hypertension in a Male Sardinian Population by Victoria L. Herrera (383897)

“…The <i>ATP1A1</i> promoter containing the 12T-insertion exhibited decreased transcriptional activity in in vitro reporter-assay systems, indicating decreased α1Na,K-ATPase expression with the 12T-insertion, compared with the 12T-deletion <i>ATP1A1</i> promoter. …”